Smell Perception: More Than Meets the Nose
Our sense of smell is often taken for granted—until it’s gone. But beyond the ability to detect pleasant aromas or avoid foul ones, smell perception plays a profound role in how we experience the world. From triggering memories to shaping emotional responses, the olfactory system is more than just a biological curiosity; it’s a gateway to connection, safety, and quality of life. At Cyrano Therapeutics, we understand just how vital this sensory system is. That’s why we’re dedicated to restoring smell perception through advanced therapies that address the root causes of sensory dysfunction. The Anatomy of Smell: Where Perception Begins To understand smell perception, we need to start with the olfactory system—an intricate network that translates airborne molecules into brain signals. When odor molecules enter the nasal passage, they bind to receptors on olfactory neurons located in the olfactory epithelium. These receptors then activate an electrical signal, which travels via the olfactory nerve to the olfactory bulb. The olfactory bulb acts like a relay station, refining these signals and sending them to various brain regions. The result? Our conscious perception of scent. Even minor damage to this pathway can impair our ability to detect and interpret smells. Smell and the Brain: The Emotional and Memory Connection What makes smell perception unique among the senses is its direct connection to the brain’s emotional and memory centers. Odor signals are processed not just in the sensory cortex but also in the amygdala and hippocampus—areas responsible for emotional regulation and memory formation. This is why a whiff of a certain perfume can instantly transport us back to childhood, or why the smell of a favorite meal can evoke powerful emotions. These connections underscore how deeply ingrained smell is in our cognitive and emotional landscape. When Perception Breaks Down: Causes of Dysfunction Unfortunately, the olfactory system is vulnerable to various types of damage. Viral infections (such as COVID-19), head trauma, chronic sinus conditions, and neurodegenerative diseases can all impair smell perception. According to 2022 statistics, millions of people experience anosmia (complete loss of smell) or hyposmia (reduced smell), affecting not just enjoyment of life, but also health and safety. More Than Inconvenient: Safety and Social Impacts Smell perception does more than enhance flavor—it helps keep us safe. It alerts us to dangers like smoke, spoiled food, or gas leaks. Without it, individuals may unknowingly expose themselves to serious hazards. Beyond safety, the social implications of smell loss are equally significant. Food-centered gatherings, shared meals, and cultural traditions often rely on taste and aroma. Losing that connection can lead to social withdrawal, anxiety, and even depression. The Future of Smell Perception Therapy At Cyrano Therapeutics, we’re on the frontlines of developing regenerative therapies that address the root causes of smell loss. Our clinical-stage treatments aim to reawaken the olfactory system by targeting the cellular and molecular mechanisms responsible for perception. We believe that restoring smell perception goes beyond a medical goal—it’s about helping people reconnect with life.
Press Release March 2025
Cyrano Therapeutics and Resyca Announce Exclusive License Agreement for Soft Mist Nasal Spray Technology for the Treatment of Chemosensory Dysfunction DELRAY BEACH, Fla and ENSCHEDE, Netherlands, March 18, 2025 /PRNewswire/ — Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, and Resyca, a leading innovator in soft mist inhaler and soft nasal spray technologies, today announced they have entered into an exclusive licensing agreement for Resyca’s proprietary soft mist nasal spray technology for the treatment of chemosensory disorders, including post-viral smell loss (hyposmia). This agreement marks a major milestone in advancing an innovative treatment to address this critical unmet medical need. Cyrano Therapeutics’ lead therapy, CYR-064, has progressed its Phase 2 FLAVOR clinical study utilizing Resyca’s soft mist nasal spray technology, with top-line data expected in the second half of 2025…..
Anosmia and Hyposmia: What’s the Difference and Why It Matters?
Understanding the Spectrum of Smell Loss At Cyrano Therapeutics, we are dedicated to advancing treatments for smell loss disorders, helping patients regain a sense that is often overlooked yet deeply impacts quality of life. Among the most common olfactory conditions are anosmia and hyposmia—but what exactly do these terms mean, and why is it important to differentiate between them? Both conditions affect the ability to detect odors. Understanding their differences is crucial for identifying the right diagnosis, treatment approach, and potential for recovery. What is Anosmia? Anosmia is the complete loss of the sense of smell. Individuals with anosmia are unable to detect odors at all, which can have profound effects on: Causes of Anosmia Anosmia can be caused by a variety of medical conditions, injuries, or environmental factors, including: Some cases of anosmia are temporary, while others can be permanent, depending on the cause and extent of damage to the olfactory system. What is Hyposmia? Hyposmia is the partial loss of smell, meaning individuals can still detect odors, but they are diminished in intensity or harder to recognize. Many people with hyposmia describe smells as being faint, distorted, or unrecognizable compared to how they once perceived them. Symptoms of Hyposmia People experiencing hyposmia may notice: Common Causes of Hyposmia Like anosmia, hyposmia can be triggered by infection, injury, or underlying medical conditions, including: At Cyrano Therapeutics, we are leading cutting-edge research into new therapies designed to restore olfactory function for both anosmia and hyposmia patients. Hope for Smell Loss: The Road to Recovery If you or a loved one is experiencing anosmia or hyposmia, you are not alone. Smell loss is more than just an inconvenience—it impacts daily life, safety, and well-being. But thanks to advancements in regenerative medicine, there is hope for restoring olfactory function. At Cyrano Therapeutics, we are dedicated to developing effective, evidence-based treatments that offer a path to recovery. Through cutting-edge research, clinical trials, and innovative therapies, we are working to help patients regain their sense of smell and improve their quality of life. Learn More & Stay Informed Stay up to date with the latest developments in smell loss therapy by visiting our website. If you’re interested in participating in clinical trials or learning more about our work, contact Cyrano Therapeutics today. The future of smell recovery starts here.
KYORIN and Cyrano Therapeutics Partner to Advance CYR-064
KYORIN and Cyrano Therapeutics Enter into an Option Agreement for CYR-064 for the Treatment of Post-Viral Loss of Smell in Japan Agreement Provides Cyrano Therapeutics with Upfront and Milestone Payments, Plus Royalties from Commercialization of CYR-064 in Japan Delray Beach, FL, February 18, 2025 – Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced today that on February 14, 2025 it entered into an option agreement with KYORIN Pharmaceutical Co., Ltd. for CYR-064, a novel treatment for post-viral loss of smell (hyposmia). Under this agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064 in Japan and will pay an option fee to Cyrano. Upon exercising the option and entering into a licensing agreement, KYORIN will provide Cyrano with an upfront payment, milestone payments tied to the progress of developing and commercializing CYR-064, and royalties based on a specified percentage of net sales following its launch. CYR-064, a novel, patent-protected, intranasal formulation of a broad-spectrum phosphodiesterase (PDE) inhibitor theophylline, is currently being administered in a Phase 2 clinical trial in the United States, with data from the trial expected in the second half of 2025. CYR-064 targets the inhibition of cAMP degradation thereby increasing intracellular concentrations and increasing olfactory neuron excitability, leading to a potential therapeutic effect in the treatment of post-viral hyposmia and potentially other olfactory disorders. Post-viral hyposmia is defined as a persistent olfactory dysfunction after an upper respiratory tract infection, even after the upper respiratory inflammation has subsided. A virus is the most common cause of olfactory dysfunction, followed by chronic rhinosinusitis, Parkinson’s disease and head trauma. With the loss of smell, patients also lose up to 80% of their perception of taste. Forty percent of patients with olfactory dysfunction also experience more than two safety events and 43% experience depression3, significantly reducing a patient’s quality of life. At present, there are no medications with clear evidence of effectiveness in treating post-viral hyposmia. About Hyposmia Hyposmia, including post-viral hyposmia, is an increasingly prevalent and serious chronic sensory condition for which there is no approved drug therapy and limited treatment options. Hyposmia causes significant impairment in quality of life for many sufferers. Moreover, in older individuals, hyposmia is associated with an increased risk of cognitive impairment and mortality. There is currently no FDA-approved therapy indicated for the treatment of smell loss. About KYORIN Pharmaceutical Co. Ltd. KYORIN Pharmaceutical Co., Ltd. was founded in 1923. Accelerating its evaluation and acquisition of in-licensed products and establishing a presence in designated fields, KYORIN aims to contribute broadly to people’s health by pursuing innovation in drug discovery, in order to strengthen drug discovery capability and create high-value new drugs that meet medical needs.https://www.kyorin-pharm.co.jp/en/ About Cyrano Therapeutics Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since its foundation, Cyrano has been working diligently to develop therapies for people struggling with the loss of smell and taste. To learn more, please visit cyranotherapeutics.com 1. Clinical practice guidelines for olfactory dysfunction (The Japanese rhinologic society) Japanese Journal of Rhinology 2017, 56, 487-556, 2025, 64, 1-85 2. Coelho et al. Am J of Otol.: 2021 Jul-Aug;42(4):103001 Media Contact: Tiberend Strategic Advisors, Inc. Eric Reiss [email protected]
Press Release February 2025
Press Release : Cyrano Therapeutics Announces the Launch of an Investigator-Initiated Clinical Study Evaluating CYR-064 for the Loss of Smell (Hyposmia) in Parkinson’s Disease Patients DELRAY BEACH, Fla., Feb. 4, 2025 /PRNewswire/ — Cyrano Therapuetics,inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced today that it is providing clinical material to support an investigator-led feasibility study evaluating CYR-064 in Parkinson’s Disease patients….
The Hidden Safety Hazards of Smell Loss: Protecting Yourself and Your Home
Living with anosmia, or the loss of the sense of smell, presents challenges that extend far beyond missing pleasant aromas or flavors. Smell is a vital sensory tool that helps alert us to dangers like gas leaks, fires, or spoiled food. For those living with anosmia, the absence of this warning system can increase risks in daily life. At Cyrano Therapeutics, we understand these challenges and are committed to helping individuals with anosmia live safely and confidently. Recognizing the Risks of Living with Anosmia The sense of smell serves as an early alert system for many hidden dangers. Without it, individuals with anosmia must find alternative ways to mitigate risks, including: Understanding these risks helps highlight the importance of alternative strategies to maintain safety. Practical Tips for Living with Anosmia While anosmia poses unique challenges, there are effective strategies to create a safer environment and reduce risks. Leverage Technology to Detect Hidden Hazards Modern technology offers tools that can act as substitutes for the sense of smell: Enhance Food Safety Practices Without the ability to rely on smell, a systematic approach to food safety becomes essential: Maintain a Safe Home Environment Proactive household maintenance can significantly reduce the risk of undetected hazards: Build a Routine for Safety Checks Consistency in monitoring safety devices and household systems ensures peace of mind: Staying Safe Outside the Home The challenges of anosmia don’t end at home. When dining out or traveling, it’s important to take additional precautions to stay safe: Living Confidently with Anosmia Anosmia may require adaptations, but it doesn’t have to limit your safety or quality of life. With the right tools, habits, and awareness, you can navigate daily life confidently and securely. At Cyrano Therapeutics, we’re committed to developing innovative solutions to improve the lives of those living with anosmia, while also providing practical strategies for navigating its challenges. To find out more about our work at Cyrano Therapeutics or information about our clinical trials, please contact us. We’re excited to hear from you!Together, we can help you rediscover a life of safety and confidence.
A Sense of Hope: Cyrano Therapeutics’ Mission to Restore Sense of Smell
A Sense of Hope: Cyrano Therapeutics’ Mission to Restore Sense of Smell The sense of smell is an essential part of daily life, influencing how we enjoy food, connect with others, and stay safe in our environments. For millions of people worldwide, losing this critical sense can be life-altering, impacting both physical and mental health. Cyrano Therapeutics is leading the charge in developing groundbreaking treatments to restore the sense of smell, offering hope to those who have endured this often-overlooked condition. The Growing Need for Solutions Even before the COVID-19 pandemic, the loss of smell—technically known as olfactory dysfunction—affected more than 15 million Americans. Common causes included viral infections, head injuries, and neurodegenerative diseases. Since COVID-19, the number of cases has skyrocketed, with long COVID adding thousands of new cases daily. This surge highlights the urgency of finding effective therapies to restore the sense of smell. For those affected, the condition is not just a sensory loss but a disruption to their quality of life, safety, and mental well-being. Cyrano Therapeutics is addressing this challenge head-on with innovative therapies designed to make a meaningful difference. CYR-064: Pioneering a New Path Cyrano Therapeutics’ flagship therapy, CYR-064, is a revolutionary treatment designed to restore the sense of smell. Currently undergoing a rigorous 32-week clinical trial, this placebo-controlled study aims to evaluate the safety and effectiveness of CYR-064 in treating hyposmia, the partial loss of smell. The treatment works at the molecular level, targeting the olfactory neurons responsible for detecting and processing scents. By repairing and regenerating these critical cells, CYR-064 offers a promising pathway to restoring normal olfactory function. For participants and future patients, this therapy represents hope for regaining a sense of smell—and with it, the joys and safety it brings. Why Restoring the Sense of Smell Matters The loss of smell, especially post viral smell loss, impacts more than just sensory perception; it affects how people navigate their lives. From diminished enjoyment of meals to difficulty identifying dangers like gas leaks or spoiled food, the challenges are profound. Social interactions can also suffer, leading to feelings of isolation and depression. Restoring the sense of smell is about more than physical recovery—it’s about reclaiming a fuller, safer, and more connected life. Cyrano Therapeutics understands this need and is committed to advancing solutions that address both the scientific and emotional dimensions of smell loss. Cyrano’s Commitment to Olfactory Health Beyond developing innovative treatments, Cyrano Therapeutics is dedicated to raising awareness about olfactory dysfunction and its widespread impacts. Through education, advocacy, and cutting-edge research, Cyrano is helping to prioritize olfactory health as an essential component of overall well-being. Their efforts extend beyond their laboratory. By encouraging participation in clinical trials and fostering collaboration across the medical community, Cyrano is working to create a future where restoring the sense of smell is not just a possibility but a reality for millions. A Future of Hope & Healing for Restoring a Sense Smell Cyrano Therapeutics represents a beacon of hope for individuals affected by smell loss. With its pioneering approach to restoring the sense of smell, the company is not only advancing science but also transforming lives. For those seeking to make a difference, supporting Cyrano’s mission or joining its clinical trials, for restoring a sense of smell, is an opportunity to contribute to a brighter future—one where sufferers can now smell the world around them, and with it, a renewed appreciation for the all that entails. Learn More about restoring your sense of smell today.
Exploring the FLAVOR Trial: Advancements in Restoring Smell and Taste
Loss of smell (hyposmia) due to a virus and the associated loss of taste affects more than 65 million people between the US, Europe and Japan and millions more worldwide, significantly impacting quality of life. Cyrano Therapeutics has developed an intranasal treatment to address this issue, with the first products focused on restoring olfactory function for those suffering from long-term post-viral hyposmia. The FLAVOR trial is testing an advanced nasal spray with a groundbreaking pharmaceutical formulation to help people recover their sense of smell and taste and enjoy life again. Why This Flavor Trial Matters Hyposmia can lead to difficulties in daily life, including safety concerns (like detecting gas leaks) and reduced enjoyment of food. Research has also linked smell loss to emotional and mental health challenges such as depression and anxiety. Cyrano Therapeutics is developing a therapy to restore this essential sense, which could greatly improve patients’ overall well-being. This trial is the next step in that development process. Restoring 2 of the Main 5 Senses Smell and taste represent two of the main five senses we have as human beings. While the restoration of these senses have been historically under-researched, the work being done at Cyrano Therapeutics is shifting the landscape. As we continue to lead the charge in this important area, our findings could provide hope for millions who have lost this essential sense. For updates on our clinical trials and how you can get involved, visitCyrano Therapeutics Clinical Trials.
Winter Wellness: Tips for Sense of Smell Restoration and Protection
Winter months bring an increased risk of respiratory illnesses like the flu, colds, and other viral infections, which can significantly impact your health, including your sense of smell. For those who experience post-viral olfactory dysfunction, finding effective treatments is critical. That’s why sense of smell restoration has become a major focus of ongoing research, especially at Cyrano Therapeutics, where innovations like CYR-064 offer new hope. In this article, we’ll explore the science behind smell loss, groundbreaking research, and actionable tips to protect your olfactory health during the winter season. How Winter Viruses Impact Your Sense of Smell Viral infections, such as influenza and COVID-19, can disrupt the function of your olfactory nerves, leading to a partial or total loss of smell. This condition, known as post-viral olfactory dysfunction, can persist for months or even years, affecting quality of life, safety, and mental well-being. Cyrano Therapeutics is advancing the science of loss of smell research through clinical trials like the FLAVOR trial, which investigates CYR-064, an innovative therapy designed to restore olfactory function. For individuals suffering from prolonged loss of smell, these advancements provide a much-needed pathway to recovery. Learn more about their ongoing efforts by exploring their researching smell loss programs. Groundbreaking Solutions for Smell Restoration The growing need for effective treatments has sparked innovative research in the field of olfactory dysfunction. Cyrano Therapeutics is leading the way with therapies aimed at sense of smell restoration, like CYR-064, which targets the damaged olfactory system with precision. The therapy is currently undergoing rigorous evaluation in clinical trials. Participation in such trials is a great way for individuals affected by olfactory dysfunction to contribute to medical advancements. If you or someone you know is interested, consider reaching out to Cyrano’s team for smell therapy research contact opportunities. In addition to offering groundbreaking treatments, Cyrano also invites investors interested in advancing regenerative medicine to support this vital work. Learn more about investing in regenerative medicine and how your contributions can help transform lives. Protect Your Sense of Smell This Winter While medical advancements are critical, prevention plays a significant role in maintaining your olfactory health. Here are some practical tips to reduce your risk of losing your sense of smell: If you suspect a loss of smell after an illness, act early by consulting a specialist and staying informed about treatments such as smell loss therapy research. Revolutionizing Smell Restoration With winter illness season in full swing, protecting your sense of smell is more important than ever. Taking proactive steps to support your olfactory health can help you avoid post viral smell loss, a condition that can significantly impact daily life. Whether you’re seeking treatment options or interested in supporting innovative research, Cyrano Therapeutics offers opportunities to make a meaningful impact. Reach out today to learn more about smell therapy research, contact opportunities, or invest in smell loss research. Together, we can create a brighter future for those living with olfactory dysfunction.
Cyrano Therapeutics Secures $9M for Development of Treatment for Post-Viral Smell Loss
Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell Loss. Phase 2 FLAVOR clinical trial currently enrolling 150 patients to assess the safety and effectiveness of CYR-064 in treating patients with chronic smell loss following recovery from a viral infection (post-viral hyposmia) No FDA-approved drug therapy available for this increasingly prevalent and serious chronic sensory condition Delray Beach, FL, January 16, 2024 – Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has secured a $9.0 million Series B financing to advance the development of CYR-064 as a potential first-ever treatment for post-viral smell loss (hyposmia). Co-lead investors participating in the financing include the Florida Opportunity Fund managed by DeepWork Capital and existing investors Lumira Ventures and Remiges Ventures. Cyrano intends to use the proceeds from its Series B financing to advance FLAVOR, its Phase 2, double-blind, randomized clinical trial of CYR-064, an intranasal theophylline spray therapy to treat patients who have lost their sense of smell following recovery from a viral infection. The FLAVOR Phase 2 trial will be conducted at up to 15 sites in the US and the Series B financing is to fund the trial through data readout. “This Series B financing enables us to advance what we believe to be a first-of-its-kind treatment for patients suffering from long-term smell loss due to a viral infection,” said Rick Geoffrion, President and CEO of Cyrano Therapeutics, Inc. “Smell loss correlates to functional loss of taste, which can both diminish quality of life and present significant health and safety risks, thus underscoring the urgency in advancing this important therapeutic. We also plan to conduct exploratory research for patients with Parkinson’s disease, 95 percent of whom often experience loss of smell and flavor as the first symptom of the disease.” Jackson Streeter, MD, Venture Partner at DeepWork Capital, stated: “Cyrano Therapeutics represents an important investment for DeepWork and the Florida Opportunity Fund as we seek to identify and cultivate emerging biotechnology companies in Florida that combine executive and scientific expertise with therapeutic opportunities that offer the potential to address significant, unmet medical needs. We look forward to supporting the entire Cyrano team as the company advances CYR-064 through the FLAVOR Phase 2 trial.” The number of patients experiencing long-term smell and flavor loss has increased 10-fold in the wake of the COVID-19 pandemic to more than 40 million patients in the US and Europe. Thirty percent of those suffering from smell loss will experience a hazardous event such as food poisoning or the inability to detect hazardous fumes. There is currently no FDA-approved drug therapy to treat smell loss from any cause. About Hyposmia: Hyposmia, including post-viral hyposmia, is an increasingly prevalent and serious chronic sensory condition for which there is no approved drug therapy and limited treatment options. Hyposmia causes significant impairment in quality of life for many sufferers. Moreover, in older individuals, hyposmia is associated with an increased risk of cognitive impairment and mortality. Prior to the COVID-19 pandemic, an estimated 8 million individuals in the US and Europe suffered from long-term post-viral hyposmia. The COVID-19 pandemic has resulted in dramatically increased prevalence, with an estimated 40 million individuals in the US and Europe currently suffering from long-term post-viral hyposmia. About Cyrano Therapeutics: Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop therapies for people struggling with the loss of smell and taste. About the FLAVOR Trial: The Phase 2 FLAVOR trial is a 150 subject randomized, double-blinded, placebo-controlled, multi-dose, multi-site clinical trial of CYR-064 for the treatment of post-viral hyposmia. For more information, please visit ClinicalTrials.gov About DeepWork Capital: DeepWork Capital invests professionally managed committed venture capital in growth-oriented, early-stage companies in the technology and life science sectors. We partner with visionary entrepreneurs building disruptive companies. DeepWork works closely with other investment groups and takes a hands-on approach with its portfolio companies. For additional information, please see www.deepworkcapital.com Media Contacts: Tiberend Strategic Advisors, Inc. Dave Schemelia [email protected] +1 609-468-9325 Eric Reiss [email protected] +1 802-249-1136